All analyses
AI analysis

InsureMe Insurance Brokers Limited: research report

OvervaluedbearishNov 16, 2026

Evidence points bearish because the shares trade at 79.5 times earnings, far above insurance peers. Audited return on equity of 35.7% is the main counterweight.

Reports without a focus are public, one per stock per day. Generation usually takes about 15 minutes, and we'll notify you when it's ready.

Why bearish

  • The shares trade at 79.5 times the latest audited earnings, versus a 10.5 times insurance-sector median.
  • At 24.9 times book value, the company is the most expensive of 11 sector peers on that measure.
  • The market-wide valuation score is 10 of 100, placing the share in the Overvalued band despite very thin trading.

Against this. The audited year to March 2026 delivered a 35.7% return on equity, showing that the business generated a strong return on its recorded capital.

Net margin
5.5%sector 1.4%
latest quarter
Return on equity
35.7%sector 7.2%
full year to Mar 31, 2026
P/E
72.9sector 15.6
earnings Rs 38.32 per share, year to Mar 2026
P/B
22.84sector 1.46
book Rs 122.25 per share

Current figures, updated daily from filings to Sep 30, 2026. The report below was written on Nov 16, 2026. Sector figures are the median of 11 listed companies in the same sector.

Overview

InsureMe is a technology-enabled insurance broker and aggregator, connecting customers with partner insurers for motor, travel, life and health cover. Its latest filing shows a profitable business with cash exceeding stated debt, but the share price has moved far faster than the reported earnings base. The principal corporate development is a proposed share subdivision, reported as 1:100 on 11 November 2026; it changes the number of shares, not the underlying earning power.

Price performance

The share closed at LKR 3,045 on 16 November 2026. It rose 84.0% over one month while the ASPI rose 7.7%, and gained 130.8% over six months against a 5.1% ASPI fall. The price stands at the top of its adjusted 52-week range, so the valuation is being assessed after an unusually sharp rerating rather than after a retreat.

Trading activity is exceptionally thin. Median daily turnover over 60 sessions was only LKR 35,080, and a LKR 1 million order is more than everything that trades on a typical day (2851% of it). Recent 60-day volatility was 16.0% above the company's own one-year level and 20-day volume was 145.7% above the 60-day norm, indicating that the recent advance has occurred during unusually active trading for this share.

Valuation

The market-wide valuation evidence starts bearish: InsureMe scores 10 of 100 on price against book value and earnings, placing it in the Overvalued band. The shares trade at a P/E of 79.5 times, meaning LKR 79.5 is paid for every LKR 1 of the latest audited profit, versus a sector median of 10.5 times. Its P/E is higher than 86% of comparable sector observations.

The P/B is 24.9 times, or almost LKR 25 paid for each LKR 1 of net assets, versus a 1.33 times sector median. It is the highest P/B among 11 insurance peers. The audited 35.7% ROE helps explain why the company could command a premium to book value, but not the scale of this premium relative to the sector. No dividend is on record over the last two years, so there is no yield to offset the valuation. The available record is too short to assess today's multiples against InsureMe's own valuation history.

News and sentiment

Direct coverage is thin: the 90-day record contains two material articles, both neutral. Both concern the 1:100 subdivision reported on 11 and 12 November 2026, rather than a change in operations, contracts or insurance-broking earnings.

The subdivision remains announced rather than dated. It was reported as subject to CSE concurrence and shareholder approval, so it should not be treated as completed.

Financials

The latest filed quarter, September 2026, generated revenue of LKR 162 million and net profit of LKR 9 million, down from LKR 21 million in the preceding June quarter. That sequential decline leaves less quarterly profit supporting the current share price, although no year-on-year comparison is available in the supplied data.

September gross margin was 38.5%, compared with no supplied year-ago margin. Operating margin is unavailable for the September filing, while net margin was 5.5%, again without a supplied year-ago comparator. The absence of a year-on-year measure means the latest quarter cannot be described as an improvement or deterioration against the corresponding prior-year quarter; nor is a ranked historical comparison available.

The latest audited full year ended March 2026, not the September quarter, and recorded LKR 503 million of revenue, LKR 109 million of operating profit and LKR 79 million of net profit. Gross, operating and net margins for that year were 44.3%, 21.6% and 15.7% respectively. Equity was LKR 221 million at that date, and the September balance sheet used the same 2.1 million shares now in issue, so the current per-share figures have not been mechanically altered by a completed corporate action.

Risks

The most immediate practical risk is liquidity rather than balance-sheet leverage: a LKR 1 million order exceeds a typical day's traded value, making a meaningful position difficult to build or exit through normal trading. This matters particularly after the sharp recent price move because quoted market value may not be readily transferable at normal session turnover.

For a financial-services business, total liabilities were 0.95 times equity at September 2026, modestly lower than 0.99 times at March. Cash was LKR 136 million against LKR 62 million of stated debt, but lender-style cash-flow and conventional debt-service ratios are not informative for this reporting model. The larger fundamental risk is that a small business with September quarterly profit of LKR 9 million is valued at multiples far above its insurance peer group.

Outlook

As at 16 November 2026, the next operating evidence is the December 2026 interim quarter, expected to be filed between 6 and 14 February 2027. It will show whether the lower September profit was an isolated quarterly outcome or whether the earnings base supporting the current valuation has changed.

The proposed subdivision has no ex-date set. Based on comparable exchange timing, its ex-date is expected between 12 December 2026 and 31 January 2027, subject to the required approvals; it would alter per-share presentation mechanically but does not itself create operating earnings. The supplied data cannot establish the reason for the recent share-price surge or quantify post-September trading performance.

About this report. Generated on Nov 16, 2026 from market data up to Nov 16, 2026, 2 material news articles over 90 days and financials to Sep 30, 2026, and scored 10 of 100 on value (overvalued) when it was written. Every figure is drawn from EquityLK's own data on this company. AI research can contain errors, so treat it as a starting point, not investment advice.

Previous reports